Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
暂无分享,去创建一个
[1] A. Guyton,et al. Textbook of Medical Physiology , 1961 .
[2] R. Juchems,et al. [Hemodynamics in posture changes]. , 1970, Zeitschrift fur Kreislaufforschung.
[3] C Maxwell,et al. Instant experience in clinical trials: a novel aid to teaching by simulation. , 1971, The Journal of clinical pharmacology and new drugs.
[4] G R Wilkinson,et al. Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.
[5] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[6] B T Marsh. The planning of a clinical trials workshop. , 1975, British journal of clinical pharmacology.
[7] T L Woodings,et al. Clinical trial experience by simulation: a workshop report. , 1978, British medical journal.
[8] G. Tucker,et al. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. , 1986, British journal of clinical pharmacology.
[9] J M Bland,et al. Computer simulation of a clinical trial as an aid to teaching the concept of statistical significance. , 1986, Statistics in medicine.
[10] D. Cortese,et al. Severe hypoxemia and liver disease. , 1989, The American review of respiratory disease.
[11] R. Kato,et al. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P‐450 human‐2 , 1990, Clinical pharmacology and therapeutics.
[12] G T Tucker,et al. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism. , 1990, The Annals of occupational hygiene.
[13] C. Mathias. Effect of food intake on cardiovascular control in patients with impaired autonomic function , 1990, Journal of Neuroscience Methods.
[14] G. Tucker,et al. Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. , 1991, British journal of clinical pharmacology.
[15] F. Trevisani,et al. The hemodynamic status of preascitic cirrhosis: An evaluation under steady‐state conditions and after postural change , 1992, Hepatology.
[16] Tucker Gt,et al. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. , 1992 .
[17] R. Kato,et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.
[18] S. Ohmori,et al. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. , 1993, Molecular pharmacology.
[19] M. Chiba,et al. Metabolism: Scaling-up from In Vitro to Organ and Whole Body , 1994 .
[20] G. Tucker,et al. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game". , 1994, Journal of pharmaceutical sciences.
[21] G. Tucker,et al. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. , 1996, Pharmacogenetics.
[22] T Sakaki,et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.
[23] L. Blendis,et al. The effect of posture on central blood volume in patients with preascitic cirrhosis on a sodium‐restricted diet , 1996, Hepatology.
[24] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[25] S. Imaoka,et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.
[26] S. Yamaguchi,et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.
[27] T Lavé,et al. Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.
[28] R. Weaver,et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[29] J. Lin,et al. Sense and nonsense in the prediction of drug-drug interactions. , 2000, Current drug metabolism.
[30] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[31] D. Lewis,et al. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.
[32] M. Wilson,et al. Regulation of intestinal blood flow. , 2000, The Journal of surgical research.
[33] P. Jeffrey,et al. Utility of metabolic stability screening: comparison of in vitro and in vivo clearance , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[34] H. Zhou,et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. , 2001, Acta pharmacologica Sinica.
[35] S. Ekins,et al. Application of in silico approaches to predicting drug--drug interactions. , 2001, Journal of pharmacological and toxicological methods.
[36] T Lavé,et al. Prediction of Hepatic Metabolic Clearance , 2001, Clinical pharmacokinetics.
[37] A. J. MacDonald,et al. Analysis of solvent central nervous system toxicity and ethanol interactions using a human population physiologically based kinetic and dynamic model. , 2002, Regulatory toxicology and pharmacology : RTP.
[38] H. Jick,et al. Statins and the risk of idiopathic venous thromboembolism. , 2002, British journal of clinical pharmacology.
[39] E Niclas Jonsson,et al. More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.
[40] Malcolm Rowland,et al. Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[41] T. Bjornsson,et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness , 2003, Journal of clinical pharmacology.
[42] Gunnar Johanson,et al. The Bayesian population approach to physiological toxicokinetic-toxicodynamic models--an example using the MCSim software. , 2003, Toxicology letters.
[43] Jakob Ribbing,et al. Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[44] Tommy B Andersson,et al. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. , 2004, Drug Metabolism And Disposition.
[45] Kiyomi Ito,et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.
[46] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[47] A. Rostami-Hodjegan,et al. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.
[48] Kiyomi Ito,et al. DRUG-DRUG INTERACTIONS : CYP 2 D 6 PARADIGM , 2005 .
[49] M. Jamei,et al. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] Amin Rostami-Hodjegan,et al. Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[51] Draft Guidance,et al. Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , and Implications for Dosing and Labeling DRAFT GUIDANCE , 2006 .
[52] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[53] Amir Heydari,et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA , 2006, Journal of psychopharmacology.
[54] K Rowland-Yeo,et al. Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[55] Kiyomi Ito,et al. Determination of a Human Hepatic Microsomal Scaling Factor for Predicting in Vivo Drug Clearance , 2006, Pharmaceutical Research.
[56] Amin Rostami-Hodjegan,et al. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.
[57] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[58] J. Dearden. In silico prediction of aqueous solubility , 2006, Expert opinion on drug discovery.
[59] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[60] N. Thomas. A Model Patient , 1861, BMJ : British Medical Journal.
[61] Amin Rostami-Hodjegan,et al. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. , 2007, British journal of clinical pharmacology.
[62] P. McNamara,et al. Protein binding predictions in infants , 2008, AAPS PharmSci.